Archive | April, 2010

Dendreon(DNDN) Receives FDA Approval for Therapeutic Cancer Vaccine

New Treatment Category for Cancer-Autologous Cellular Immunotherapy The FDA cleared the first therapeutic vaccine for cancer with Dendreon’s Provenge (R)(Sipuleucel-T), an individualized treatment approach for advanced prostate cancer (CRPC). CRPC is asymptomatic or minimally symptomatic, metastatic,castrate-resistant (hormone refractory) prostate cancer.Provenge takes the patient’s own immune cells and infuses them back thereby priming the immune system […]

Continue Reading 0

Milken Institute Global Conference-Healthcare Reform I

Missed Opportunity in Health Reform-Wellness and Prevention On Monday April 26 a panel of executives  and leaders including Michael Milken, moderated by CNBC anchor Maria Bartiromo convened to discuss Health Reform in a session focused on “Prevention and Cures”. The primary focus of the discussion was the need for government policy and health reform to […]

Continue Reading 0

Gilead(GILD) and Abbott(ABT) Guidance Triggers Biotech Sell-Off

Healthcare Reform Impact on Gilead HIV Product Sales Surprises Analysts Gilead Sciences (GILD) lowered its 2010 sales forecast to a range of $7.4-$7.5B from $7.6-$7.8B citing recently enacted healthcare legislation. Net income for the quarter ended March 31 jumped from $854.9M or $0.92/sh. compared with $589.1M or $0.63/sh. in the Year ago period. Gilead’s first-quarter […]

Continue Reading 0

Genomics Update from AACR: Biomarkers for Oncology Medicine

Yesterday we presented an overview of the use of  Biomarkers(BM’s) for predictive use in the treatment of Lung Cancer. Here are some additional summaries from the American Association for Cancer Research(AACR) meeting on Monday.Researchers from Fox Chase Cancer Center in Philadelphia reported on a study the suggests that levels of the enzyme ERCC1 offer  a […]

Continue Reading 0

Helicos(HLCS) Update

GenomeWeb published an update (scroll down)on Helicos on Friday April 16. Full Year Revenues for fiscal 2009 were $3M and although R&D and Admin expenses were cut the Net Loss for the Year was $28M. Helicos has been working with the investment bank Thomas Weisel Partners since last summer to explore strategic alternatives.On April 14 […]

Continue Reading 0

Genomics Update: Biomarkers Help Select Personalized Oncology Medicine

At yesterday’s AACR (American Association of Cancer Research) Meeting in Washington DC researchers presented results from the Battle Trial which is a hypothesis- driven prospective study that identifies biomarkers(BM’s) to predict tumor response and thus helps select personalized therapy for lung cancer patients.Biopsy specimens were tested for  eleven biomarkers from four NSCLS pathways:EGFR,KRAS,BRAF and VEGF.The […]

Continue Reading 0

Goldman Charge Curbs Enthusiasm for Market Risk

Larger Cap Healthcare Stocks Holding Up Well The SEC charges against Goldman Sachs have taken the MO out of the market with speculative issues down considerably. As of midday trading the Dow is down 1.2%. NASDAQ down 1.5% and the S&P down 1.6%.Stocks are off their lows. Large Cap healthcare and biotech stocks were less […]

Continue Reading 0

Rayno Life Science Portfolio 2010: Biopharmaceuticals

Exelixis (EXEL) added as speculative buy at $3.30 on 9/2/10 Update: Portfolio rebalancing below but we are still in a bearish mode with small cap biotech. The brief rally spurred by a potential buyout rumor by Sanofi last Friday has evaporated with Biogen,Celgene Genzyme and Gilead all down. The IBB is flat for the year. […]

Continue Reading 0

Rayno Life Science Portfolio : Diagnostics and Tools, Quidel and Celera

Quidel (QDEL) was up 7.9% yesterday to $12.13 on volume of 375k shares. This stock is now under review and is a value buy in the $12 range. Quidel bought Diagnostic Hybrids for for $131M in Q1 bringing debt to $83M. Wedbush upgraded the stock on May 27. Celera(CRA) is being added as a buy […]

Continue Reading 0

Immucor(BLUD) Profits Up but Stock Down 8 %

Immucor (BLUD) a global leader in providing instrument-reagent systems to the blood transfusion industry  delivered more than expected financial results for the 3rd Quarter of fiscal 2010 ended February 28. Revenue of $80.5M was up 7% from prior year quarter. Gross margin was 69.2% compared to prior year quarter of 71.4%. Diluted earnings per share […]

Continue Reading 0